{"id":1387,"date":"2024-12-18T07:30:44","date_gmt":"2024-12-18T07:30:44","guid":{"rendered":"https:\/\/www.doctaforum-events.org\/2025\/emma2025\/?page_id=1387"},"modified":"2025-08-27T06:36:46","modified_gmt":"2025-08-27T06:36:46","slug":"saturday-september-6","status":"publish","type":"page","link":"https:\/\/www.doctaforum-events.org\/2025\/emma2025\/saturday-september-6\/","title":{"rendered":"Saturday, September 6"},"content":{"rendered":"<p><!--<span style=\"display: inline-block; width: 0px; overflow: hidden; line-height: 0;\" data-mce-type=\"bookmark\" class=\"mce_SELRES_start\"><\/span><span style=\"display: inline-block; width: 0px; overflow: hidden; line-height: 0;\" data-mce-type=\"bookmark\" class=\"mce_SELRES_start\"><\/span>&nbsp;\n\n&nbsp;\n\n&nbsp;\n\n&nbsp;\n\n&nbsp;\n\n\n<p style=\"text-align: center;\"><span style=\"font-size: 20pt;\">COMING SOON<\/span><\/p>\n\n\n&nbsp;\n\n&nbsp;\n\n&nbsp;\n\n&nbsp;\n\n&nbsp;\n\n&nbsp;\n\n&nbsp;\n\n--><\/p>\n<div id=\"\" class=\"panel-group\">\n<div class=\"panel panel-default\">\n<div class=\"panel-heading\">\n<div class='panel_hour d-flex align-items-center'>\n<h4 class=\"panel-title \">09:00 &#8211; 10:35<\/h4>\n<\/p><\/div>\n<div class='title_panel col d-flex align-items-center'>\n<h4 class=\"panel-title\">PLENARY SESSION 7: MANAGEMENT OF THE RELAPSED PATIENT<\/h4>\n<\/p><\/div>\n<\/p><\/div>\n<div id=\"collapse2\" class=\"panel-collapse collapse in\">\n<table id=\"tablepress-15\" class=\"tablepress tablepress-id-15\">\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-1\">\n\t<td class=\"column-1\"><span class=\"moderator\">Moderator<\/span><\/td><td class=\"column-2\"><span class=\"clase2\">Jes\u00fas F. San-Miguel<\/span><\/td>\n<\/tr>\n<tr class=\"row-2\">\n\t<td class=\"column-1\">09:00 - 09:20<\/td><td class=\"column-2\"><span class=\"clase1\">How should I treat relapsed patients (with approved drugs)?<\/span><br \/>\n<span class=\"clase2\">Michel Delforge<\/span><\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">09:20 - 09:40<\/td><td class=\"column-2\"><span class=\"clase1\">Bispecific and ADC : when and how?<\/span><br \/>\n<span class=\"clase2\">Paula Rodr\u00edguez -Otero<\/span><\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">09:40 - 10:00<\/td><td class=\"column-2\"><span class=\"clase1\">CAR-T cells and other adoptive therapies: when and how?<\/span><br \/>\n<span class=\"clase2\">Hermann Einsele<\/span><\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">10:00 - 10:20<\/td><td class=\"column-2\"><span class=\"clase1\">Are new pathways to be targeted in Myeloma?<\/span><br \/>\n<span class=\"clase2\">Enrique Ocio<\/span><\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">10:20 - 10:35<\/td><td class=\"column-2\"><span class=\"clase1\">Experts' discussion around 5 burning topics:<\/span><br \/>\n<ol class=\"programs-lists\"><br \/>\n<li><span class=\"clase1\">1. Biological relapse versus aggressive relapse<\/span><\/li><br \/>\n<li><span class=\"clase1\">2. Triplet versus doublets: is it cost-effective?<\/span><\/li><br \/>\n<li><span class=\"clase1\">3. Is CAR-T the future? alone or combined with anti-MM drugs?<\/span><\/li><br \/>\n<li><span class=\"clase1\">4. Bispecific antibodies or CAR-T<\/span><\/li><br \/>\n<li><span class=\"clase1\">5. Industry or academia<\/span><\/li><br \/>\n<\/ol><\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\"><\/td><td class=\"column-2\"><span class=\"clase2\">Discussants:  Dr. San-Miguel, Dr. Delforge, Dr. Rodr\u00edguez-Otero, Dr. Einsele, Dr. Ocio, Dr. Kastritis,  Dr. Yong<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<!-- #tablepress-15 from cache --><\/div>\n<\/div>\n<div class=\"panel panel-default\">\n<div class=\"panel-heading colorgris\">\n<div class='panel_hour d-flex align-items-center'>\n<h4 class=\"panel-title \">10:35 &#8211; 10:55<\/h4>\n<\/p><\/div>\n<div class='title_panel col d-flex align-items-center'>\n<h4 class=\"panel-title\">Break<\/h4>\n<\/p><\/div>\n<\/div>\n<\/div>\n<div class=\"panel panel-default\">\n<div class=\"panel-heading coloramarillo\">\n<div class='panel_hour d-flex align-items-center'>\n<h4 class=\"panel-title \">10:55 &#8211; 12:10<\/h4>\n<\/p><\/div>\n<div class='title_panel col d-flex align-items-center'>\n<h4 class=\"panel-title\">PLENARY SESSION 8: HOW I TREAT OTHER MALIGNANT GAMMOPATHIES<\/h4>\n<\/p><\/div>\n<\/div>\n<div id=\"collapse4\" class=\"panel-collapse collapse in\">\n<table id=\"tablepress-16\" class=\"tablepress tablepress-id-16\">\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-1\">\n\t<td class=\"column-1\"><span class=\"moderator\">Moderator<\/span><\/td><td class=\"column-2\"><span class=\"clase2\">Jes\u00fas F. San-Miguel<\/span><\/td>\n<\/tr>\n<tr class=\"row-2\">\n\t<td class=\"column-1\">10:55 - 11:15<\/td><td class=\"column-2\"><span class=\"clase1\">Amyloidosis: what should I know?<\/span><br \/>\n<span class=\"clase2\">Ram\u00f3n Lecumberri<\/span><\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">11:15 - 11:35<\/td><td class=\"column-2\"><span class=\"clase1\">Waldenstrom macroglobulinemia: what should I know?<\/span><br \/>\n<span class=\"clase2\">Efstathios Kastritis<\/span><\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">11:35 - 11:55<\/td><td class=\"column-2\"><span class=\"clase1\">EHA-2025 Guidelines: how can help me in my daily practice<\/span><br \/>\n<span class=\"clase2\">Evangelos Terpos<\/span><\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">11:55 - 12:10<\/td><td class=\"column-2\"><span class=\"clase1\">Questions &amp; discussion<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<!-- #tablepress-16 from cache --><\/div>\n<\/div>\n<div class=\"panel panel-default\">\n<div class=\"panel-heading coloramarillo\">\n<div class='panel_hour d-flex align-items-center'>\n<h4 class=\"panel-title \">12:10 &#8211; 12:20<\/h4>\n<\/p><\/div>\n<div class='title_panel col d-flex align-items-center'>\n<h4 class=\"panel-title\">CLOSING REMARKS<\/h4>\n<\/p><\/div>\n<\/div>\n<div id=\"collapse4\" class=\"panel-collapse collapse in\">\n<table id=\"tablepress-17\" class=\"tablepress tablepress-id-17\">\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-1\">\n\t<td class=\"column-1\"><span class=\"clase2\">Jes\u00fas F. San-Miguel<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<!-- #tablepress-17 from cache --><\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>09:00 &#8211; 10:35 PLENARY SESSION 7: MANAGEMENT OF THE RELAPSED PATIENT 10:35 &#8211; 10:55 Break 10:55 &#8211; 12:10 PLENARY SESSION 8: HOW I TREAT OTHER MALIGNANT GAMMOPATHIES 12:10 &#8211; 12:20 CLOSING REMARKS<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-1387","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.doctaforum-events.org\/2025\/emma2025\/wp-json\/wp\/v2\/pages\/1387"}],"collection":[{"href":"https:\/\/www.doctaforum-events.org\/2025\/emma2025\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.doctaforum-events.org\/2025\/emma2025\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.doctaforum-events.org\/2025\/emma2025\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.doctaforum-events.org\/2025\/emma2025\/wp-json\/wp\/v2\/comments?post=1387"}],"version-history":[{"count":8,"href":"https:\/\/www.doctaforum-events.org\/2025\/emma2025\/wp-json\/wp\/v2\/pages\/1387\/revisions"}],"predecessor-version":[{"id":1571,"href":"https:\/\/www.doctaforum-events.org\/2025\/emma2025\/wp-json\/wp\/v2\/pages\/1387\/revisions\/1571"}],"wp:attachment":[{"href":"https:\/\/www.doctaforum-events.org\/2025\/emma2025\/wp-json\/wp\/v2\/media?parent=1387"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}